RxDoctor Payments Data

Elina Levkoff, MD

Family Medicine · Palm Beach Gardens, FLNPI 1376973156

Payments from drug & device makers

$3,516in general payments, 2019–2025

Across 168 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$494
  • Amgen$343
  • Pfizer$266
  • UCB, Inc.$224
  • AstraZeneca$179
  • Lundbeck LLC$176
  • plus $2K from 35 others

What the payments were for

  • Speaking & faculty fees$1143%
  • Food & beverage$3,40297%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,516 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$101,640
Medicare patients
434
Services billed
1,813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$107,725
MounjaroTirzepatide61$78,979
OzempicSemaglutide27$40,085
XareltoRivaroxaban31$33,724
JardianceEmpagliflozin20$24,861
TrulicityDulaglutide11$19,012
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,233
FarxigaDapagliflozin Propanediol12$10,948
JanuviaSitagliptin Phosphate12$8,774
Atorvastatin Calcium578$4,906
SynthroidLevothyroxine Sodium49$4,304
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$4,016
Omeprazole190$2,977
Rosuvastatin Calcium237$2,791
Levothyroxine Sodium306$2,458

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$266$107,72587 claims
Lilly USA, LLCMounjaro, Trulicity$58$97,99172 claims
Novo NordiskOzempic$134$40,08527 claims
Johnson & JohnsonXarelto$13$33,72431 claims
GSKTrelegy Ellipta$30$13,23313 claims
AstraZenecaFarxiga$179$10,94812 claims
MerckJanuvia$19$8,77412 claims
AbbVieSynthroid, Armour Thyroid$494$5,68766 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$27$2,458306 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →